This time it's a couple of ethics professors who feel that Northfield's current trial of its blood substitute, PolyHeme, "fails to meet ethical and regulatory standards."
Every week another damaging article appears. I wonder if the short sellers are mounting a campaign.
No comments:
Post a Comment